Literature DB >> 34269799

CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.

Matteo Grioni1, Arianna Brevi1, Elena Cattaneo1, Alessandra Rovida2, Jessica Bordini2, Maria Teresa Sabrina Bertilaccio3, Maurilio Ponzoni3,4, Giulia Casorati5, Paolo Dellabona5, Paolo Ghia2,4, Matteo Bellone1, Arianna Calcinotto1.   

Abstract

Chronic lymphocytic leukemia (CLL) is caused by the progressive accumulation of mature CD5+ B cells in secondary lymphoid organs. In vitro data suggest that CD4+ T lymphocytes also sustain survival and proliferation of CLL clones through CD40L/CD40 interactions. In vivo data in animal models are conflicting. To clarify this clinically relevant biological issue, we generated genetically modified Eμ-TCL1 mice lacking CD4+ T cells (TCL1+/+AB0), CD40 (TCL1+/+CD40-/-), or CD8+ T cells (TCL1+/+TAP-/-), and we monitored the appearance and progression of a disease that mimics aggressive human CLL by flow cytometry and immunohistochemical analyses. Findings were confirmed by adoptive transfer of leukemic cells into mice lacking CD4+ T cells or CD40L or mice treated with antibodies depleting CD4 T cells or blocking CD40L/CD40 interactions. CLL clones did not proliferate in mice lacking or depleted of CD4+ T cells, thus confirming that CD4+ T cells are essential for CLL development. By contrast, CD8+ T cells exerted an antitumor activity, as indicated by the accelerated disease progression in TCL1+/+TAP-/- mice. Antigen specificity of CD4+ T cells was marginal for CLL development, because CLL clones efficiently proliferated in transgenic mice whose CD4 T cells had a T-cell receptor with CLL-unrelated specificities. Leukemic clones also proliferated when transferred into wild-type mice treated with monoclonal antibodies blocking CD40 or into CD40L-/- mice, and TCL1+/+CD40-/- mice developed frank CLL. Our data demonstrate that CD8+ T cells restrain CLL progression, whereas CD4+ T cells support the growth of leukemic clones in TCL1 mice through CD40-independent and apparently noncognate mechanisms.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34269799      PMCID: PMC8341348          DOI: 10.1182/bloodadvances.2020003795

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  56 in total

1.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

2.  BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.

Authors:  Tomoyuki Endo; Mitsufumi Nishio; Thomas Enzler; Howard B Cottam; Tetsuya Fukuda; Danelle F James; Michael Karin; Thomas J Kipps
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

3.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

Review 4.  Chronic lymphocytic leukaemia: from genetics to treatment.

Authors:  Francesc Bosch; Riccardo Dalla-Favera
Journal:  Nat Rev Clin Oncol       Date:  2019-11       Impact factor: 66.675

5.  Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.

Authors:  Yun Chen; Liguang Chen; Jian Yu; Emanuela M Ghia; Michael Y Choi; Ling Zhang; Suping Zhang; Elsa Sanchez-Lopez; George F Widhopf; Karen Messer; Laura Z Rassenti; Catriona Jamieson; Thomas J Kipps
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

6.  Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

Authors:  Andreas Agathangelidis; Nikos Darzentas; Anastasia Hadzidimitriou; Xavier Brochet; Fiona Murray; Xiao-Jie Yan; Zadie Davis; Ellen J van Gastel-Mol; Cristina Tresoldi; Charles C Chu; Nicola Cahill; Veronique Giudicelli; Boris Tichy; Lone Bredo Pedersen; Letizia Foroni; Lisa Bonello; Agnieszka Janus; Karin Smedby; Achilles Anagnostopoulos; Helene Merle-Beral; Nikolaos Laoutaris; Gunnar Juliusson; Paola Francia di Celle; Sarka Pospisilova; Jesper Jurlander; Christian Geisler; Athanasios Tsaftaris; Marie-Paule Lefranc; Anton W Langerak; David Graham Oscier; Nicholas Chiorazzi; Chrysoula Belessi; Frederic Davi; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos
Journal:  Blood       Date:  2012-03-13       Impact factor: 22.113

7.  CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules.

Authors:  L E Van den Hove; S W Van Gool; P Vandenberghe; M Bakkus; K Thielemans; M A Boogaerts; J L Ceuppens
Journal:  Leukemia       Date:  1997-04       Impact factor: 11.528

8.  B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.

Authors:  Xiao-jie Yan; Emilia Albesiano; Nicola Zanesi; Sophia Yancopoulos; Alan Sawyer; Egidio Romano; Aleksandar Petlickovski; Dimitar G Efremov; Carlo M Croce; Nicholas Chiorazzi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

9.  Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells.

Authors:  Audun Os; Simone Bürgler; Anna Parente Ribes; Ane Funderud; Dong Wang; Keith M Thompson; Geir E Tjønnfjord; Bjarne Bogen; Ludvig A Munthe
Journal:  Cell Rep       Date:  2013-08-08       Impact factor: 9.423

10.  Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies.

Authors:  Sabina Sangaletti; Claudio Tripodo; Paola Portararo; Matteo Dugo; Caterina Vitali; Laura Botti; Carla Guarnotta; Barbara Cappetti; Alessandro Gulino; Ilaria Torselli; Patrizia Casalini; Claudia Chiodoni; Mario P Colombo
Journal:  Oncoimmunology       Date:  2014-06-05       Impact factor: 8.110

View more
  3 in total

Review 1.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells.

Authors:  Serena Matis; Martina Rossi; Lorenzo Brondolo; Martina Cardillo; Daniele Reverberi; Rosanna Massara; Monica Colombo; Adalberto Ibatici; Emanuele Angelucci; Tiziana Vaisitti; Silvia Bruno; Sonia Fabris; Antonino Neri; Massimo Gentile; Fortunato Morabito; Giovanna Cutrona; Paola Briata; Roberto Gherzi; Franco Fais
Journal:  Hematol Oncol       Date:  2021-10-28       Impact factor: 4.850

3.  Loss of AID exacerbates the malignant progression of CLL.

Authors:  Avery C Lee; Sai Ravi Pingali; Javier A Pinilla-Ibarz; Michael L Atchison; Constantinos Koumenis; Yair Argon; Andrei Thomas-Tikhonenko; Carl De Trez; Chih-Chi Andrew Hu; Chih-Hang Anthony Tang
Journal:  Leukemia       Date:  2022-08-30       Impact factor: 12.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.